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Abstract
Background: Maternal smoking is the most significant cause of preventable complications during pregnancy, with
smoking cessation during pregnancy shown to increase birth weight and reduce preterm birth among pregnant
women who quit smoking. Taking into account the fact that the number of women who smoke in Greece has
increased steadily throughout the previous decade and that the prevalence of smoking among Greek females is
one of the highest in the world, smoking cessation should be a top priority among Greek health care professionals.
Methods/Design: The Maternal Smoking Cessation during Pregnancy Study (M-SCOPE), is a Randomized Control
Trial (RCT) that aims to test whether offering Greek pregnant smokers a high intensity intervention increases
smoking cessation during the third trimester of pregnancy, when compared to a low intensity intervention.
Prospective participants will be pregnant smokers of more than 5 cigarettes per week, recruited up to the second
trimester of pregnancy. Urine samples for biomarker analysis of cotinine will be collected at three time points: at
baseline, at around the 32
nd week of gestation and at six months post partum. The control group/low intensity
intervention will include: brief advice for 5 minutes and a short leaflet, while the experimental group/intensive
intervention will include: 30 minutes of individualized cognitive-behavioural intervention provided by a trained
health professional and a self-help manual especially tailored for smoking cessation during pregnancy, while
counselling will be based on the ‘’5 As.’’ After childbirth, the infants’ birth weight, gestational age and any other
health related complications during pregnancy will be recorded. A six months post-partum a follow up will be
performed in order to re-assess the quitters smoking status.
Discussion: If offering pregnant smokers a high intensity intervention for smoking cessation increases the rate of
smoking cessation in comparison to a usual care low intensity intervention in Greek pregnant smokers, such a
scheme if beneficial could be implemented successfully within clinical practice in Greece.
Trial Registration: ClinicalTrials.gov Identifier NCT01210118
Background
Tobacco use among women and during pregnancy
Tobacco consumption is the main cause of preventable
death globally with tobacco considered to be the only
consumer product legally on sale that kills such a high
percentage of its users [1]. Epidemiological studies over
the last 30 years have concluded that the total mortality
of smokers is increased within the range of 50% to
116%, depending on the smokers’ age, their average
tobacco consumption and their years as a smoker [2].
As a result smoking kills one third to half of all smo-
kers, who die on average 15 years earlier than their non
smoking peers [3]. In 2000 it was estimated that 4.83
million premature deaths worldwide were caused by
smoking, with the main causes of death attributable to:
cardiovascular disease, lung cancer and chronic
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deaths attributable to tobacco use greater than the num-
ber of deaths due to drug use, alcohol consumption,
AIDS, car accidents, suicides and murders combined
[4-6].
While, it has been estimated that 10 million female
deaths were attributable to tobacco use between 1950
and 2000, the projected number of deaths attributable
to smoking among women over the next 30 years is esti-
m a t e dt ob em o r et h a nd o u b l et h a to ft h ep r e v i o u s5 0
years [7]. This increase in mortality is attributable to the
increase in female smoking rates, which subsequently
leads to a higher percentage of women who smoke dur-
ing their reproductive years and thus during the early
stages of pregnancy (before it being verified) and a smal-
ler percentage will continue to smoke throughout the
gestational period.
Maternal smoking during pregnancy is also the most
significant cause of preventable complications during
pregnancy [8]. Active maternal smoking has been asso-
ciated with a number of adverse pregnancy outcomes,
such as premature birth and perinatal mortality [9]. The
perinatal mortality rate has been identified to be 150%
greater when the mother is a smoker [10], and it has
been suggested that smoking is responsible for 15% of
all cases of premature birth [11]. Moreover, perinatal
mortality is increased among the offspring of pregnant
smokers regardless of the number of cigarettes daily
smoked, while this risk is reduced to an important
degree when pregnant women stop smoking before the
last trimester of pregnancy [12].
Since the first research performed in 1957[13], mater-
nal active smoking during pregnancy has been shown to
effect fetal birth weight and fetal growth (such as in
height, head perimeter, perimeter of thorax and
shoulders) and thus affect the growth of the lungs and
brain, with possible ramifications that could continue
into later life [14-17]. Active maternal smoking during
pregnancy has been also shown to predispose infants
towards the development of other health related issues,
such as Sudden Infant Death Syndrome (SIDS) [18,19],
infant’s respiratory function [20-22] aid the development
of asthma in childhood [23] and asthmatic bronchitis
during the first year of life [24].
Smoking cessation interventions during pregnancy and
their benefits
Recognizing the importance of this problem, the issue of
aiding or promoting smoking cessation during preg-
nancy is imminent. Furthermore, smoking cessation dur-
ing pregnancy is economically beneficial, due both to
the improvement of maternal health, as also due to its
direct impact on improving infants’ health [25].
Research has indicated that women who quit smoking
during the first 3-4 months of pregnancy, give birth to
infants of similar weight to those that never smoked
[26,27]. As assessed through a recent systematic review
carried out by Lumley et al. interventions for smoking
cessation increase the mean birth weight of infants by
33 g (95% CI 11 g to 55 g) and simultaneously reduce
preterm birth (pooled RR 0.84,95% CI: 0.72 to 0.98)
[28]. These children during their development are likely
to have a reduced need for health care and suffer less
from chronic diseases and thus in general be of greater
benefit to the health care system [29,30]. Indeed, if all
pregnant women who smoke 15 or more cigarettes per
day stopped smoking it has been estimated that 5% of
hospital admissions of children less than 8 months
could be prevented [31].
While 40% of pregnant women stop smoking sponta-
neously prior to their first visit to their gynaecologist
and the verification of their pregnancy, the remaining
continue to smoke, with the majority known to simply
reduce their cigarette consumption [25,32-34]. It is
these women that continue to smoke during pregnancy
which should be targeted to participate in smoking ces-
sation programs during pregnancy. Increasing the
awareness of pregnant smokers in regards to pregnancy
outcomes and their new social role as mothers, makes
pregnancy a “teachable moment,” which is important for
smoking cessation, as their receptivity towards smoking
cessation messages is increased [35].
The majority of smoking cessation interventions con-
verges on providing information on the effects of active
smoking on the foetus, emphasizing the advantages of
quitting smoking. However, interventions may vary
depending on their intensity and approach with com-
mon procedures either basic oral counselling [36,37],
the provision of self-help manuals booklets or the com-
bination of the above [37,38]. In regards to the intensity
of the performed intervention, in most studies an inten-
sive intervention lasting more than 15 minutes has been
found to be more effective [39-41] than shorter and less
individualized interventions, which are described in
some studies as “low intensity interventions” and in
others as “usual care” (< 5 minutes) [39,40,42-44]. In a
systematic review and meta-analysis performed to evalu-
ate the most effective and shortest counselling interven-
tion for smoking cessation during pregnancy, a more
intensive intervention was identified as more effective, if
comprised of 15 minutes of cognitive-behavioural orien-
tation accompanied by printed material [45]. The effec-
tiveness of a manual of clinical guidelines for smoking
cessation during pregnancy and the role of patient edu-
cation has been previously evaluated, through which the
provision of a self-help manual, a videotape and a brief
counselling intervention were found to be more effective
in promoting cessation in comparison to the provision
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8.8% in the control group) [44].
Hypothesis/aim of the current study
Greece has one of the highest percentages of smoking at a
global level, with the percentage of adult female smokers
estimated in 2007 at 31.3%, but with geographical differ-
ences within parts of the country [45,46]. While smoking
prevalence among men over the past few decades has
dropped in Greece (from 54% in 1984 to 47% in 1998), the
prevalence among women has increased from 19.5% in
1984 to 29% in 1998 [47].What is even more alarming
though, is the fact that currently smoking prevalence does
not differ by gender in Greece among youth and adoles-
cents, which indicates the need for action to promote
smoking prevention and tobacco cessation activities at a
national level [48]. With the tobacco epidemic in Greece
in mind, the aim of the M-SCOPE study was to create and
assess a smoking cessation programme tailor-made for
Greek women who smoke during pregnancy that could be
applied within the Greek health care system.
Overall, the aim of this clinical trial is to test whether
offering pregnant smokers a single high intensity inter-
vention for smoking cessation:
a) Increases the rate of smoking cessation during late
pregnancy.
b) Has an effect on adverse birth outcomes attributa-
ble to smoking.
c) May promote retaining a smoke free status after
childbirth.
d) May reduce the concentrations of circulating bio-
markers (cotinine/nicotine) and possibly tobacco related
carcinogens, namely 4-(methylnitrosamino)-1-(3-pyri-
dyl)-1-butanol (NNAL) during pregnancy.
Methods/Design
Design - Setting
The M-SCOPE study is a randomized controlled trial with
a parallel assignment approach that compares the efficacy
of a proactive pregnancy-tailored high intensity interven-
tion for smoking cessation, which is the experimental
group, with a usual care low intensity intervention, which
is the control condition. This research will take place
(November 2009-June 2012) in two hospitals situated in
the area of Attica, Greece namely through the Peripheral
General Maternity Hospital ‘Elena Venizelos’ (137/04-10-
0 7 )a n dt h eM a t e r n i t yU n i to ft h e‘Attikon’ University
Hospital within Athens (287/30-07-09). Randomisation
will be computer generated while the participants will not
be aware of their intervention group (single blind).
Eligibility/Study population
The study population should follow the below criteria in
order to be considered eligible to participate, namely: a)
currently pregnant, b) currently cigarette smokers of > 5
cigarettes over the past 7 days, and c) > 18 years old.
Exclusion criteria include: a) a gestational age > 24 weeks’
gestation at the time of entry, b) limited or no telephone
access, c) not planning to live at the same address for 1
year, d) unable to read and/or speak Greek fluently, e)cur-
rent alcohol or substance abusers (defined as strong crav-
ings for alcohol, inability to limit drinking, continued use
of alcohol despite the repeated problems) [49], and f) cur-
rent depression (according to the Greek validated version
of the Goldberg’s General Health Questionnaire (GHQ)
[50,51].
Data collection points
The different points in this research protocol are
described analytically below and illustrated in the study
design flowchart depicted in Figure 1.
The first contact (the baseline assessment), will take
place before the 24
th week of gestation during which
prospective participants will be informed about the
research aims and procedures, while demographic data
and smoking habits are to be recorded.
During the baseline interview the following demo-
graphic variables will be recorded: age, weeks of gesta-
tion, marital status, ethnicity educational level, current
work status. In addition to the above, smoking related
data will also be collected (current and past smoking
habits, age of smoking initiation, duration of smoking in
years, number of cigarettes smoked before pregnancy and
currently, partner’s smoking habits, prior attempts to quit
smoking and duration of these attempts. Furthermore,
exposure to secondhand smoke at home, at work and in
public places is also to be assessed. Smoking status will
be biochemically validated through expired Carbon Mon-
oxide (CO), while urine samples of the participants will
be obtained for biomarker analysis. Additionally during
the baseline assessment, the Fagerstrom test for Nicotine
dependence [52] and the Greek version of Goldberg’s
General Health Questionnaire (the 28 question version)
are also to be completed [50,51]. During this initial meet-
ing, the intervention will be provided
During the second contact, participants of both groups
will receive a follow up phone call before the 32
nd week of
gestation so as to schedule a second meeting (around the
32
nd week of gestation) during which the participants
smoking status will be assessed by both self- report and
urine sample analysis, which will be collected on that day.
The third contact will take place around childbirth,
during which data on birth outcomes and pregnancy
complications will be collected.
Finally, six months post-partum, the quitters’ post par-
tum relapse will be assessed during a meeting through
which smoking status will be reported and again bio-
chemically verified.
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Control group participants will receive a face to face low
intensity intervention which lasts 5 minutes and will
include brief advice and the provision of a leaflet on
smoking and pregnancy. This leaflet summarizes the
main effects of smoking during pregnancy and gives
clear short messages for encouraging smoking cessation
by setting up a quit date.
Figure 1 Study Design Flowchart.
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intensity intervention, which include: 30 minutes of
individualized cognitive-behavioural counselling deliv-
ered by a trained health care professional and a self-help
manual especially tailored for smoking cessation during
pregnancy. Counseling will be based at the “5 Αs” (Ask,
Advise, Asses, Assist, Arrange). The “5A s ” are based on
the “four steps” by Glynn and Manley [53] recom-
mended by the US National Cancer Institute The
importance of the “5A s ” in counselling is corroborated
by their recommendation by the US Department of Pub-
lic Health towards health professionals [33]. Further-
more, in 2010 the American College of Obstetricians
and Gynaecologists suggested the “5 Αs” as the interven-
tion of choice for smoking cessation as it is considered
short and easy to use [54].
In addition to counselling, a self help manual espe-
cially tailored for smoking cessation during pregnancy
for Greek women will be provided. According to Lan-
caster and Stead’s systematic review’s [55] a self-help
manual provides structured materials (printed or audio-
visual) that assist the individual in making an attempt to
quit and sustaining abstinence without significant assis-
tance from health professionals. For instance, self-help
can be provided through printed, video, telephone
(recorded messages) or computer-based materials [56].
In most studies a self-helpm a n u a li sa ni n f o r m a t i v e
booklet, that is initially presented and explained, and
then provided to the pregnant woman to take with her
and thus can be consulted and read at home
[57,58,41,42,59-62]. Such a self-help manual is not lim-
ited to providing information about the effects of smok-
ing on the foetus, the potential complications during
pregnancy and adverse outcomes in childbirth, but also
includes the effects of smoking on women’sh e a l t ho r
the role of infant second-hand smoke exposure in order
to prevent a smoking relapse post-partum [62].
Our self help manual creation was based on the above
general rules and principles taking into consideration
Greek cultural particularities. In our effort to make a
simple but interesting and scientifically oriented self-
help manual, photos were included as well and refer-
ences for further reading were provided. The self-help
manual of our protocol was divided into four parts. The
first part summarized the key points in regards to the
effects of smoking during pregnancy on the foetus, but
also of the gain acquired through smoking cessation, the
benefits for maternal health and how to prevent relapse,
and stay smoke free. Also during the first section a
“Questions and Answers” list was included based on
common queries brought forward, such as the best time
to quit, breast-feeding issues, weight gain, etc. The sec-
ond part of the self help manual was aimed to prepare
the pregnant woman to quit by providing practical
solutions for handling cravings and nervousness, the
importance of the involvement of the partner and the
women’ss o c i a ln e t w o r k .T h en e x ts t e pi nt h em a n u a l
(third section) was about setting a smoking cessation
date. Some general practical suggestions are included as
well as some special suggestions for the quit date. More
emphasis is given to the strength of her will to remain
abstinent. Moreover, on the last page of the self help
manual the CDC’s document entitled ‘’within 20 min-
utes of quitting’’ is referenced, which descriptively illus-
trates what happens to one’s body 20 minutes after
smoking his/her last cigarette [63].
Biochemical validation and its justification
Despite the availability of biochemical tests, some stu-
dies still accept the trueness of smoking cessation
reported by smokers without biochemical validation,
even though several studies have refuted the claims of
pregnant women through biochemical tests due to high
miss reporting [39,64,65]. The importance of biochem-
ical validation of smoking cessation during pregnancy is
summarized in a previous systematic literature review,
which included 72 RCTs conducted from 1975 to 2008
involving more than 25,000 pregnant smokers, that con-
cluded that studies that do not biochemically validate
the smoking status of pregnant women almost certainly
have substantial measurement errors and therefore
should be considered unreliable [28]. Within the context
of our study, smoking status will be both self reported
and validated: at the baseline assessment, at around the
32nd week of gestation and approximately 6 months
after delivery only for the woman who successfully quit.
Urinary nicotine and cotinine are commonly used to
assess exposure to tobacco products. While nicotine has
a half-life of only 2-3 hours and can only inform us
about recent exposure to tobacco smoke, cotinine (due
to its longer half life of 15-19 hours) is a preferred mar-
ker of choice [66] Moreover, expired Carbon Monoxide
(CO) will be also measured during the encounters.
Expired CO will be measured by the Micro Smokerly-
zer
® CO monitor (Bedfont Scientific Ltd). The same
regularly calibrated CO tester will be used for each mea-
surement (Micro CO Tester, Micro Medical Ltd.,
Rochester, Kent, UK). The expired air CO measurement
will be performed according to detailed written guide-
lines, while the person who will perform the measure
will have been trained beforehand. Even though expired
CO is a convenient, low-cost measurement, that may
provide immediate results for the evaluation of smoking
status [67], its short half-life (3-6 hours) can lead to
false negatives [68] as it is able to detect only smokers
who have smoked within the past several hours and
therefore cannot be considered the most reliable bio-
chemical marker for confirming the validity of smoking
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women to quit. [67].
Description of the laboratory analysis technique
Urine cotinine and nicotine concentrations will be
assessed through liquid chromatography mass spectro-
metry (LC/MS) analysis based on previously applied
methods [69,70]. Samples after collection will be allo-
cated into vials and stored at -20 degrees Celsius until
the analysis. In order to ensure and increase internal
validity the urine cotinine and nicotine analysis will be
performed in a separate collaborating laboratory who
will be blinded in regards to participant smoking status
(smoker/quitter), study group (intervention/control) and
sample collection date (pre/post intervention).
Reagents
(-)-nicotine (99%) and (-)-cotinine (98%) will be obtained
from Sigma-Aldrich (St. Louis, USA). Acetonitrile (LC-
MS grade Chromasolv) will be obtained from Fischer
Scientific UK Limited (Leicestershire, UK). Ammonium
formate (99%), ammonium acetate (98%), methanol (LC-
MS grade Chromasolv) and water (LC-MS grade Chro-
masolv) will be purchased from Fluka Analytical (Stein-
heim, Germany). Ammonia (25%) will be obtained from
Merck (Darmstadt, Germany). Furthermore, solid phase
extraction tubes (BOND ELUT-C18, 100 mg, 1 ml) will
be purchased from Varian Inc.
LC MS analysis
All analyzes will be performed using a liquid chromato-
graph mass spectrometer (Shimadzu LCMS - 2010 EV)
system equipped with an atmospheric pressure chemical
ionization (APCI) interface, an autosampler, solvent
degasser, binary pump, and a heated/cooled column
compartment. The column is a Discovery C18 HPLC
Column (25 cm × 4.6 mm, 5 μm, SupelCo, (Bellefonte,
USA). Both mass spectrometer and HPLC inlet will be
controlled by Shimadzu LCMS solution software (LCMS
Solution version 3) which also will be used for data
acquisition and processing. The instrument will be
tuned and calibrated using autotune procedures recom-
mended by the manufacturer. The detector voltage will
be regulated at 1.5 kV and the nebulizing gas flow at 2.5
L/min.
Ten μl( 1 0μl) from each extracted sample will be
entered to the chromatograph column, at temperature
45°C. A gradient of 10 mM ammonium acetate, pH =
5.0, (solvent A) and an acetonitrile (solvent B) are
selected for routine use: starting at 10% of solvent B,
90% B (15 min linear ramp), 10% B (5 min). The total
mobile phase flow rate will be 0.6 mL/min. The detec-
tion will be done in the SIM (selected ion monitoring)
positive mode using ion fragments with m/z 163, 204
for nicotine, m/z 177, 218 for cotinine and m/z 238, 279
for ketamine.
Outcome Measures
The primary outcome assessed will be the participants’
smoking status during the 32
nd week of gestation. Sec-
ondary outcomes include: birth outcomes (such as the
infants’ birth weight, prematurity of birth, complications
during pregnancy) as also smoking relapse among quit-
ters 6 months post partum. Possibly their urinary
tobacco specific carcinogens pre/post intervention will
be assessed.
Sample size - Statistical analyses
Sample size was determined based on pilot research
during which the rate of smoking cessation was signifi-
cantly higher in the experimental group (25%) than in
the control group (7%). Assuming that in our entire
research project might have similar rates of smoking
c e s s a t i o ni nb o t hg r o u p sa n df o rap o w e ro f8 0 %a n da
significance level of 0.05 this implied a sample size of
128 pregnant smokers.
Statistical analyses will be performed using Statistical
Package for the Social Sciences (PASW) version 18.
With regard to the process evaluation, descriptive statis-
tics will be used, such as frequencies, means, standard
deviations and ranges. General descriptive statistics will
be used to describe the participants’ demographic data,
participants’ general and mental health and nicotine
dependence, while bivariate and multivariate analyses
will also be performed.
Quality Control
Reliability and validity are considered to be the criteria
for assessing the quality of quantitative studies. So as to
assure the above, the RCT’s randomization list will be
kept concealed until the participants’ assignment to
each group and will be computer generated. After the
informed consent form has been signed a study entry
number will be assigned to each participant. This num-
ber will be on the outside of an envelope, which will
allocate accordingly the participant to either the experi-
mental or the control group (single blind allocation).
Allocation concealment will prevent the occurrence of
selection bias and randomization sequence before and
until interventions are provided to the prospective parti-
cipants [71].
Ethical Considerations
Prospective participants will have been informed both
verbally and in writing about the aims, the methods, the
procedures and the measurements performed during
this study. They will also be informed about ethical
issues such as confidentiality, their right to ask any
questions during the study and their right to withdraw
at any time. In order to ensure that all participants have
received information about this research project and
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a written consent form. In all instances research will
adhere to the criteria of the World Medical Association
Declaration of Helsinki [72].
This research has been approved by the Biomedical
Ethics Committee of the Faculty of Medicine of the
National and Kapodistrian University of Athens (Proto-
col approval number: 4568/07-01-08) as also by the
Ethics committee of both participating hospitals the Per-
ipheral General Maternity Hospital ‘Elena Venizelos’
(Protocol approval number: 137/04-10-07) and the
Maternity Unit of the ‘Attikon’ University Hospital
within Athens (Protocol approval number: 287/30-07-
09). Furthermore the M-SCOPE study trial is registered
through clinicaltrials.gov (ClinicalTrials.gov Identifier:
NCT01210118).
Implications
The scope of this study is not only to identify the most
effective intervention for smoking cessation during preg-
n a n c yi nG r e e c ew i t ht h eu s eo fb i o c h e m i c a lm e a s u r e -
ments, but also to develop such a research protocol for
smoking cessation among Greek pregnant women that
could be applied within other health care settings in
Greece.
T h er e s u l t so ft h i ss t u d ya r ei m p o r t a n ta st h e yc o u l d
be successfully implemented in clinical practice within
Greece, where organized smoking cessation programmes
for pregnant smokers are not provided. These pro-
grammes could be potentially helpful for both pregnant
smokers and their immediate family but also beneficial
to the health care system as the cost of such a smoking
cessation intervention would likely be minimal in com-
parison to the treatment of the well known health
effects of maternal smoking during pregnancy.
Strengths and Limitations
Our study has some important strengths, which are the
study design itself (an RCT), and the fact that this is
the first RCT to be applied in regards to smoking ces-
sation among pregnant Greek women. Additionally the
biochemical verification of smoking status and the col-
lection of biological samples for further analysis also
add to the study’s strength and research possibilities.
On the other hand one possible limitation of this study
is that light smoking might be misreported by preg-
nant smokers, as smoking during pregnancy is not
socially accepted and the fact that it is difficult to dis-
tinguish at a biomarker level light smoking from heavy
exposure to second hand smoke. Another limitation
that should be taken into account is the fact that the
curriculum of this study may not be generalisable to
other countries due of the different cultural
background.
Conclusion
Considering the continuous steady increase in the pre-
valence of Greek female smokers, such research is
needed so as to provide the Greek population with a
smoking cessation programme which can be applied
within primary health care and maternity care, utilising
the “teachable moment” of pregnancy, protecting infants
and their mothers from smoking related diseases.
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